The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Dupilumab rapidly treated and maintained improvements in lichenification, a type of skin thickening from repetitive ...

Dupilumab had a fivefold improvement in sustained disease remission in bullous pemphigoid compared with placebo, along with a significant reduction in oral corticosteroid use.

In this randomized, placebo-controlled replicate trial, depemokimab decreased the annual rate of exacerbations among patients ...